genuine question about retatrutide that I am slightly embarrassed to ask
genuine question about retatrutide that I am slightly embarrassed to ask. Searched first, found three threads that contradict each other, hence the post. The thing that surprised me was how much of the discussion here is inference rather than measurement. Watched heart rate on a wearable across twelve weeks because…
Trial names corrected in the title. The phase 3 programme and the phase 2 readout are not the same thing.
heart rate is the thing people report watching
the glucagon component is why the metabolic story reads differently
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
Stopped at a low step because there was no reason to go further and no data to tell me what further would do.
the escalation is where most of the reported trouble sits
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.